Similarly, the randomized, controlled HUYGENS study was conducted to assess the impact of the proprotein convertase subtilisin kexin type-9 (PCSK-9) inhibitor evolocumab on atherosclerosis regression in patients treated with the maximum statin dose (NCT03570697) [41]. This evidence concerns the gene PCSK9 and atherosclerosis.